CO2 Indirect Treatment Comparison between Daprodustat and Roxadustat in Non-Dialysis Patients with Anemia Associated with Chronic Kidney Disease: An Analysis of Energy/Fatigue as Measured by the SF-36 Vitality Score

A Singh,A Sackeyfio,Rd Lopes,Cp Kovesdy,I Dasgupta,Dc Wheeler,A Cases,A Wiecek,S Mallett,N Ballew,Rk Israni,T Keeley,V Garcia-Horton,R Ayyagari,R Refoios Camejo,Kl Johansen

doi:10.1016/j.jval.2022.04.100

CO2 Indirect Treatment Comparison between Daprodustat and Roxadustat in Non-Dialysis Patients with Anemia Associated with Chronic Kidney Disease: An Analysis of Energy/Fatigue as Measured by the SF-36 Vitality Score

A Singh, A Sackeyfio + Show 14 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.100

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 25, 2022
License type: publisher-specific-oa

Affiliation: Brigham and Women's Hospital, GlaxoSmithKline (United Kingdom), Duke Medical Center, University of Tennessee Health Science Center, University Hospitals Birmingham NHS Foundation Trust, University College London, Spanish Society of Hematology and Hemotherapy, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, University of Barcelona, Medical University of Silesia, GlaxoSmithKline (United States), Analysis Group (United States), Hennepin Healthcare Research Institute, University of Minnesota

#Prolyl Hydroxylase Inhibitors #SF-36 Vitality Score + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Prolyl hydroxylase inhibitors (PHIs) are oral agents that might increase availability of anemia treatment options for patients with chronic kidney disease (CKD). The 36-Item Short Form (SF-36) Vitality score is a patient-reported measure of energy/fatigue – common and important outcomes in patients with CKD. Direct comparative evidence on health-related quality of life from randomized controlled trials (RCTs) between PHIs has not been identified. We conducted an indirect treatment comparison (ITC) of changes in SF-36 Vitality score observed in placebo-controlled RCTs of daprodustat and roxadustat.

Full Text